Shares of Pfizer Inc., the world’s largest drug maker, sank Monday on news that the company had halted development of a key new cholesterol treatment that was heralded as the engine to re-ignite the company’s stagnant sales.

The stock plunged $3.63, or 13 percent, to $24.23 in morning trading on the New York Stock Exchange.